TNFRSF8 and anaplastic large cell lymphoma: Except for brentuximab vedotin, a CD30-directed antibody-drug conjugate that has shown promising results against CD30-positive ALCL (5), the effect of other approved drugs, such as pralatrexate and romidepsin, is not satisfactory, with response rates and durations of clinical benefit of 25%-29% and 10-17 months, respectively.